Trading Statement

Cyprotex Trading Update

13 December 2012 - Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today provides an update on trading following the Company's interim results on 6 September 2012.

For the first half of the year, Cyprotex announced a 5.1% increase in revenues to £3.72m with an operating loss of £189,000. While revenues up to the month of October were as expected, late November and December performance have been slightly softer than expected due to a delay in customers sending the compounds prior to the extended Christmas holiday period.

Revenues are ahead of 2011 comparables and the Company continues to trade profitably, however, we expect revenues will be slightly below market expectations with a commensurate drop in profit.

For further information:

Notes to Editors

About Cyprotex PLC

Cyprotex is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 700 partners ranging from small biotechs to large pharma companies. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information, see www.cyprotex.com.